A new wave of psoriasis treatments is pushing the boundaries of what dermatologists once thought possible, with several drugs now achieving total skin clearance in more than half of patients enrolled in clinical trials. In the KNOCKOUT trial, published in Nature Communications in December 2025, higher-than-approved induction doses of risankizumab cleared the skin completely in 83.3 percent of participants by week 28, while the oral TYK2 inhibitor zasocitinib helped over 50 percent of patients reach near-total clearance in separate Phase 3 trials involving more than 1,800 participants across 21 countries. For the millions of people living with moderate-to-severe plaque psoriasis, these results represent a genuine shift. Complete clearance, measured as a PASI 100 score, was once considered an aspirational target rather than a realistic treatment goal.
Now multiple drugs across different mechanisms of action are hitting that mark in significant numbers. This matters for brain health, too. Chronic inflammatory conditions like psoriasis have been linked in epidemiological research to increased risks of cognitive decline and dementia, making effective disease control relevant well beyond the skin. This article examines the drugs driving these results, from injectable biologics to the first oral cytokine blockers, what the clinical data actually shows, the limitations worth knowing about, and what these advances could mean for people managing psoriasis alongside other health concerns.
Table of Contents
- Which New Psoriasis Drugs Are Achieving Total Skin Clearance in Over Half of Patients?
- How Do Oral Psoriasis Treatments Compare to Injectable Biologics?
- The Inflammation-Brain Connection and Why Psoriasis Control Matters for Cognitive Health
- Combination Therapy and the Push Beyond Monotherapy Results
- Limitations and Cautions in Interpreting These Results
- What the Shift Toward Oral Biologics Means for Patients and Caregivers
- What Comes Next in Psoriasis Treatment
- Conclusion
- Frequently Asked Questions
Which New Psoriasis Drugs Are Achieving Total Skin Clearance in Over Half of Patients?
The standout performer in recent data is risankizumab, marketed as Skyrizi, an IL-23 inhibitor already approved for psoriasis at a 150 mg dose. In the KNOCKOUT trial, researchers tested higher induction doses of 300 mg and 600 mg in a small phase 2 study of 20 patients, randomized evenly between the two dose arms. At week 28, 83.3 percent achieved PASI 100, meaning their skin was completely clear of psoriasis plaques. An even more striking 94.4 percent reached PASI 90, or near-total clearance. No new safety concerns emerged compared to the standard approved dose. What makes the risankizumab data particularly interesting is the durability of response after patients stopped receiving the drug.
At week 52, a full 36 weeks after the last dose, 44.4 percent of patients still had completely clear skin. Even at week 100, some 84 weeks after their final injection, two patients, representing 11.1 percent of the group, maintained total clearance. That kind of lasting response without ongoing treatment is unusual in dermatology and raises questions about whether higher induction doses might fundamentally alter the disease course rather than simply suppressing symptoms. Zasocitinib, an oral TYK2 inhibitor developed by Takeda, also crossed the threshold. In two pivotal Phase 3 trials enrolling 693 and 1,108 participants respectively, over 50 percent of patients achieved PASI 90 at week 16, with approximately 30 percent reaching full PASI 100 clearance. Response rates continued climbing through week 24. Both trials met all primary and ranked secondary endpoints versus placebo, including measures of static Physician Global Assessment and PASI 75.
How Do Oral Psoriasis Treatments Compare to Injectable Biologics?
The emergence of effective oral options is perhaps the most consequential development in this new treatment wave. Zasocitinib is a once-daily pill, not an injection, which eliminates a significant barrier for many patients. The most common adverse events reported in Phase 3 trials were upper respiratory tract infections and acne, side effects that most patients and clinicians would consider manageable. Takeda has announced plans to submit a New drug Application to the FDA in fiscal year 2026, which could make it one of the first oral TYK2 inhibitors available for plaque psoriasis. Johnson and Johnson’s icotrokinra represents an even more novel approach. It is the first oral IL-23 receptor blocker, a class of treatment that until now required injection. In the Phase 3 ICONIC-LEAD trial, 27 percent of patients taking the 200 mg once-daily oral peptide achieved PASI 100 at week 16 compared to less than 1 percent on placebo.
Thirty-three percent achieved IGA 0, or complete clearance by investigator assessment, versus just 1 percent on placebo. Half of the treated patients reached PASI 90, and 65 percent achieved IGA 0 or 1. These results, published in the New England Journal of Medicine in 2025, enrolled both adults and adolescents aged 12 and older. However, it is worth noting that oral options have not yet matched the top-line clearance rates of high-dose injectable biologics. Risankizumab at higher doses cleared 83 percent of patients completely, while icotrokinra reached 27 percent for total clearance and zasocitinib around 30 percent. For patients who need the highest possible chance of complete clearance, injectables may still hold an edge. But for patients who struggle with injection anxiety, travel frequently, or simply prefer a daily pill, oral therapies achieving PASI 90 in half or more of patients represent a meaningful alternative that did not previously exist.
The Inflammation-Brain Connection and Why Psoriasis Control Matters for Cognitive Health
Psoriasis is not merely a skin disease. It is a systemic inflammatory condition driven by overactive immune pathways, particularly involving interleukins like IL-17 and IL-23. The same inflammatory mediators that fuel psoriatic plaques circulate throughout the body and can cross the blood-brain barrier, contributing to neuroinflammation. Population-level studies have found that people with severe psoriasis face a modestly elevated risk of developing dementia compared to age-matched controls without the condition, even after adjusting for shared risk factors like cardiovascular disease and diabetes. this connection makes aggressive psoriasis treatment relevant to brain health conversations.
When a drug like risankizumab suppresses IL-23 signaling effectively enough to clear the skin completely, it is also reducing the overall inflammatory burden on the body. Whether that translates directly into reduced dementia risk has not been proven in randomized trials, and it would be irresponsible to claim certainty on that front. But the biological plausibility is strong enough that dermatologists and neurologists are increasingly paying attention to each other’s literature. For a patient in their 50s managing both psoriasis and early cognitive concerns, achieving complete skin clearance is not vanity. It may represent one actionable lever for reducing systemic inflammation during the years when brain health trajectories are being set.
Combination Therapy and the Push Beyond Monotherapy Results
Eli Lilly has been exploring whether combining psoriasis treatments with metabolic drugs can push clearance rates even higher. In the TOGETHER-PsO Phase IIIb trial, patients receiving Taltz, an IL-17A inhibitor, alongside Zepbound, a GIP/GLP-1 receptor agonist originally developed for weight management, achieved PASI 100 at a rate of 40.6 percent. That compared to 29 percent with Taltz alone, representing a 40 percent relative increase in complete skin clearance. This combination approach reflects a growing recognition that psoriasis severity is influenced by metabolic factors, particularly obesity, which increases inflammatory cytokine production and can reduce the effectiveness of biologic therapies. The tradeoff is complexity.
Adding a second medication means managing two sets of potential side effects, two dosing schedules, and higher treatment costs. For patients with both psoriasis and obesity or type 2 diabetes, the combination could address multiple conditions simultaneously. For lean patients with psoriasis alone, the additional benefit may not justify the added medication burden. Clinicians weighing combination strategies will need to consider the whole patient picture, including cognitive health. GLP-1 receptor agonists like tirzepatide, the active ingredient in Zepbound, are being studied independently for potential neuroprotective effects, which adds another dimension to the risk-benefit calculation for patients concerned about long-term brain health.
Limitations and Cautions in Interpreting These Results
The most dramatic clearance numbers come with important caveats. The KNOCKOUT trial enrolled only 20 patients, making it far too small to draw definitive conclusions about safety or efficacy at a population level. While 83 percent clearance is remarkable, results from phase 2 trials with limited enrollment frequently look better than what emerges in larger phase 3 studies and real-world practice. The higher doses of risankizumab used in KNOCKOUT are not currently approved, and there is no timeline for regulatory submission at those dose levels. Even the larger trials have limitations that matter in clinical practice.
Phase 3 studies typically exclude patients with significant comorbidities, active infections, or concurrent use of other immunosuppressants. The patients who enroll tend to be healthier and more adherent than the broader psoriasis population. Clearance rates in real-world settings, where patients are older, sicker, and less reliably followed, are generally lower than what trials report. For older adults, particularly those already managing cognitive decline or taking medications for neurological conditions, drug interactions and immunosuppression risks become more salient. IL-23 and TYK2 inhibitors work by dampening specific arms of the immune system. In a population already vulnerable to infections, the calculus around aggressive immunomodulation requires careful individualized assessment rather than reflexive pursuit of the highest clearance rates.
What the Shift Toward Oral Biologics Means for Patients and Caregivers
The development of oral options like zasocitinib and icotrokinra has particular relevance for patients whose psoriasis management is complicated by cognitive or functional limitations. Administering a subcutaneous injection requires a degree of dexterity, planning, and sometimes refrigerated storage that can be challenging for patients with dementia or those living in care facilities.
A daily pill is a fundamentally simpler intervention to integrate into an existing medication routine. Caregivers managing psoriasis on behalf of a family member with cognitive impairment will find oral treatments easier to supervise and administer. The icotrokinra data from the ICONIC-LEAD trial, which included adolescents aged 12 and older, also suggests that these oral approaches may eventually serve a wide age range, though geriatric-specific data remains limited and will be essential before drawing conclusions about use in elderly populations.
What Comes Next in Psoriasis Treatment
The pipeline for 2026 and beyond suggests this acceleration in treatment options will continue. Takeda’s planned NDA submission for zasocitinib could bring the first oral TYK2 inhibitor to market, while ongoing trials of icotrokinra will determine whether oral IL-23 blockade can narrow the efficacy gap with injectable biologics. Researchers behind the KNOCKOUT trial have raised the provocative possibility that high-dose induction might achieve something closer to a functional cure by depleting tissue-resident memory T cells that perpetuate the disease.
For patients and clinicians following this space, the practical takeaway is that treatment goals should be revised upward. Complete clearance is no longer a best-case scenario reserved for a lucky few. It is becoming a realistic target for a substantial proportion of patients, with both injectable and oral options to match different preferences and clinical situations. The challenge now is ensuring that these advances reach the patients who need them, including those whose psoriasis intersects with cognitive health concerns that make simplicity and reduced inflammatory burden especially valuable.
Conclusion
The psoriasis treatment landscape has entered a new chapter. High-dose risankizumab achieved total skin clearance in over 83 percent of patients in the KNOCKOUT trial, oral options like zasocitinib and icotrokinra are delivering clearance rates that would have been remarkable for injectables just a decade ago, and combination approaches are pushing results further still. For people managing psoriasis alongside concerns about brain health and cognitive aging, these developments carry added significance, as sustained reduction in systemic inflammation may offer benefits that extend beyond the skin.
The road from clinical trial to clinical practice always involves adjustments. Real-world clearance rates will likely be more modest, access and cost will remain barriers, and long-term safety data for newer agents is still accumulating. But the direction is clear: the question is shifting from whether complete clearance is achievable to how to achieve it most efficiently and safely for each individual patient. Anyone currently dissatisfied with their psoriasis treatment should know that the options available today, and those arriving soon, are substantially better than what existed even two years ago.
Frequently Asked Questions
Can psoriasis treatments reduce dementia risk?
There is no direct clinical trial evidence that psoriasis treatments lower dementia risk. However, severe psoriasis increases systemic inflammation, which is a known contributor to neurodegeneration. Treatments that effectively reduce this inflammatory burden are biologically plausible candidates for indirect cognitive benefit, but this remains an area of active research rather than established fact.
Are the new oral psoriasis drugs as effective as injectable biologics?
Not yet at the highest end. Injectable risankizumab at higher doses achieved 83.3 percent total clearance, while oral zasocitinib reached approximately 30 percent PASI 100 and icotrokinra reached 27 percent. However, oral options achieved PASI 90 (near-total clearance) in around 50 percent of patients, which represents a strong result for a pill-based treatment and may be sufficient for many patients.
When will zasocitinib be available?
Takeda has announced plans to submit a New Drug Application to the FDA in fiscal year 2026. If accepted and approved, it could become available within one to two years after submission, though regulatory timelines are inherently uncertain.
Is high-dose risankizumab approved for psoriasis?
No. Risankizumab (Skyrizi) is currently approved at a 150 mg dose for plaque psoriasis. The 300 mg and 600 mg doses tested in the KNOCKOUT trial are investigational. The trial was a small phase 2 study with only 20 patients, and larger studies would be needed before any regulatory submission at higher doses.
Are these new treatments safe for older adults with cognitive conditions?
The clinical trials for these drugs generally enrolled healthier adults and did not specifically study populations with dementia or significant cognitive impairment. Older adults considering these treatments should discuss immunosuppression risks, drug interactions, and monitoring requirements with both their dermatologist and any specialists managing neurological conditions.
What was the most common side effect reported with zasocitinib?
The most commonly reported adverse events in the Phase 3 trials of zasocitinib were upper respiratory tract infections and acne. The drug met all primary and secondary endpoints against placebo across two large trials enrolling more than 1,800 participants.
